Skip to main content

Table 1 Common characteristics of the studies

From: Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer

Trial   Type Follow up time (y) Previous treatment Extended treatment N Menopausal State Lymph Node (+) ER+ and/ or PR Primary endpoint
E4181/E5181 (1996) NR Full article 5.6 TAM 5y TAM 5y 100 Premenopausal /Postmenopausal 100/100 73% ER+ DFS
    TAM 5y   93 93/93   
NSABP-B14 (2001) III Full article 6.8 TAM 5y TAM 5y 593 Premenopausal /perimenopausal /Postmenopausal Negative ER+ DFS
    TAM 5y Placebo 5y 579 Negative ER+  
Scottish trial (2001) NR Full article 15.0 TAM 5y TAM 5y 173 Premenopausal /Postmenopausal 43/90a 66/173b DFS
    TAM 5y   169 35/89 66/169  
ATLAS (2013) III Full article 15.0 TAM 5y TAM 5y 3428 Premenopausal /perimenopausal /Postmenopausal 1474/3428 ER+ DFS
    TAM 5y   3418 1427/3418 ER+  
aTTom (2013) III Abstract 8.6 TAM 5y TAM 5y 3468 Premenopausal /Postmenopausal NR ER+/untested DFS
    TAM 5y   3485    
MA.17 (2005) III Full article 2.5 TAM 5y LET 5y 2593 postmenopausal 1171/2583 2516/2583 DFS
    TAM 5y Placebo 5y 2594 1189/2587 2519/2587  
NSABP-B33 (2008) III Full article 2.5 TAM 5y EMT 5y 799 postmenopausal 384/799 775/799 DFS
    TAM 5y Placebo 5y 799 384/779 759/799  
NSABP-B42 (2016) III Abstract 6.9 AI 5y LET 5y 1959 postmenopausal NR 1959/1959 DFS
    TAM 3y-AI 2y Placebo 5y 1964   1964/1964  
MA-17R (2016) III Full article 6.3 AI 4.5–6 y LET 5y 959 postmenopausal 492/959 945/959 DFS
    TAM-AI 4.5–6 y Placebo 5y 959 494/959 950/959  
ABCSG-6a (2007) III Full article 5.2 TAM5y ANA 3y 387 postmenopausal 132/387 371/387 DFS
    TAM 5y   469 146/469 454/469  
DATA (S1–03) (2016) III Abstract 4.1 TAM 2–3y ANA 6y 931 postmenopausal 561/827 827/827 DFS
    TAM 2–3y ANA 3y 929 551/827 833/833  
IDEAL(S1–04) (2017) III Abstract 6.4 (AI/TAM/TAM -AI) 5y LET 5y NR postmenopausal partial positive HR+ DFS
    (AI/TAM/TAM -AI) 5y LET 2.5y NR    
  1. TAM tamoxifen, AI aromatase inhibitor, EMT exemestane, LET letrozole, ANA anastrozole, ER estrogen, HR hormone receptor, DFS disease free survival